BC Week In Review | Feb 1, 2019
Company News

Aduro reducing headcount by 37%, focusing on STING

Aduro Biotech Inc. (NASDAQ:ADRO) said it will reduce headcount by 37% to focus on discovery and development of compounds against STING, via its deals with Novartis AG (NYSE:NVS; SIX:NOVN) and Eli Lilly and Co. (NYSE:LLY),...
Items per page:
1 - 1 of 1